Serum macroprolactin levels in pregnancy and association with thyroid autoimmunity

BMC Endocrine Disorders

Gurcan Kisakol¹  Arif Bayram Hacihasanoğlu¹  Ebru Vatansever³  Sinem Kiyici²  Soner Cander¹  Metin Guclu¹ 

[1]Department of Endocrinology and Metabolism, Sevket Yilmaz Research and Education Hospital, Bursa, Turkey

[2]Department of Internal Medicine, Sevket Yilmaz Research and Education Hospital, Bursa, Turkey

[3]Department of Biochemistry, Sevket Yilmaz Research and Education Hospital, Bursa, Turkey

关键词: Thyroid autoimmunity;    Thyroid dysfunction;    Macroprolactin;    Prolactin;    Pregnancy;   

Others  :  1215935
DOI  :  10.1186/s12902-015-0025-2

 received in 2015-03-01, accepted in 2015-06-01,  发布年份 2015

【 摘 要 】

Bacground

To assess the contribution of macroprolactin to high serum prolactin levels and their association with thyroid status and thyroid autoimmunity during pregnancy.

Methods

138 pregnant women who suspected of having thyroid dysfunction were studied and divided into three groups according to the thyroid status; group 1; euthyroidism (n 40), group 2; hypothyroidism (n 54), and group 3; hyperthyroid (n 44). Polyethylene glycol (PEG) precipitation method was used for detection of macroprolactin. A percentage recovery of 40 % or less is considered as macroprolactinemia. If macroprolactin was negative, the percentage of monomeric prolactin recovery (monoPRL %) after PEG precipitation was used for comparison between the groups.

Results

Macroprolactinemia was found in two patients (1.4 %) one from hypothyroid and other from euthyroid group. Basal prolactin levels in these patients were 400 and 403 ng/mL respectively. Referring to all patients, there was no correlation between PRL, macroPRL or monoPRL % with thyroid hormone status and also with the serum levels of thyroid antibodies (p > 0.05). A positive correlation was observed between the serum levels of PRL with TSH (p = 0.014 and r = 0.219), while a negative correlation was found with FT4 (p = 0.011 and r = −0.227).

Conclusions

Despite the fact that serum prolactin levels were found to be high during pregnancy, the contribution of macroprolactin was found to be insignificant in our study. Unlike other auto immune diseases, we could not find any relationship between thyroid autoimmunity and PRL, macroPRL or monoPRL %. These results confirmed that measured prolactin was quite homogeneous during pregnancy.

【 授权许可】

   
2015 Guclu et al.

【 参考文献 】

• [1]Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000; 80:1523-631.
• [2]Molitch ME. Prolactin in Human Reproduction. In: Jerome F Strauss III, Robert Barbieri, editors. Yen & Jaffe’s reproductive endocrinology: physiology. athophysiology and clinical management. 7th Edition. Chapter 3. Philadelphia, USA; 2013. p. 45–65.e11.
• [3]Shiu RPC, Friesen HG. Mechanism of action of prolactin in the control of mammary gland function. Annu Rev Physiol. 1980; 42:83-96.
• [4]Pansini F, Bergamini CM, Malfaccini M, Cocilovo G, Linciano M, Jacobs M et al.. Multiple molecular forms of prolactin during pregnancy in women. J Endocrinol. 1985; 106:81-5.
• [5]Glezer A, Soares CR, Vieira JG et al.. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab. 2006; 91:1048-55.
• [6]Chawla R et al.. Detection of macroprolactinemia and molecular characterization of prolactin isoforms in blood samples of hyperprolactinemic women. J Med Biochem. 2012; 31(1):19-26.
• [7]Bell DA, Hoad K, Leong L et al.. A high pressure liquid chromatography method for separation of prolactin forms. Ann Clin Biochem. 2012; 49:285-8.
• [8]Beltran L, Fahie-Wilson MN, McKenna TJ et al.. Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clin Chem. 2008; 54:1673-81.
• [9]Fahie-Wilson M, Smith TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab. 2013; 27(5):725-42.
• [10]Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev. 1997; 18:404-33.
• [11]Chen L, Hu R. Thyroid autoimmunity and miscarriage: a meta analysis. Clin Endocrinol (Oxf). 2011; 74:513-9.
• [12]Männistö T, Mendola P, Reddy U, Laughon SK. Thyroid disease and adverse pregnancy outcomes in a contemporary US cohort. J Clin Endocrinol Metab. 2013; 98:2725e33.
• [13]Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R et al.. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011; 21:1081-125.
• [14]De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH et al.. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97:2543-65.
• [15]Chang DL, Pearce EN. Screening for maternal thyroid dysfunction in pregnancy: a review of the clinical evidence and current guidelines. J Thyroid Res. 2013; 2013:851326.
• [16]Turankar S, Sonone K, Turankar A. Prolactin and thyroid levels in primary infertility. J Clin Diagn Res. 2013; 7(5):794-6.
• [17]Binita G, Suprava P, Mainak C, Koner BC, Alpana S. Correlation of prolactin and thyroid hormone concentration with menstrual patterns in infertile women. J Reprod Infertil. 2009; 10(3):207-12.
• [18]Jara LJ et al.. Prolactin and autoimmunity. Clin Rev Allergy Immunol. 2011; 40(1):50-9.
• [19]Hedi O et al.. Prolactin and autoimmunity. Clin Rev Allergy Immunol. 2012; 42(2):189-98.
• [20]Mario G-C et al.. Thyroid disorders, hyperprolactinemia and systemic lupus erythematosus activity. Int J Clin Rheumatol. 2014; 9(5):441-7.
• [21]Onal ED, Saglam F, Sacikara M, Ersoy R, Cakir B. Thyroid autoimmunity in patients with hyperprolactinemia: an observational study. Arq Bras Endocrinol Metabol. 2014; 58(1):48-52.
• [22]Kasum M, Oreskovic S, Zec I, Jezek D, Tomic V, Gall V et al.. Macroprolactinemia: new insights in hyperprolactinemia. Biochemiamedica. 2012; 22(2):171-9.
• [23]Kasum M, Pavičić-Baldani D, Stanić P, Orešković S, Sarić JM, Blajić J et al.. Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol. 2014; 183:28-32.
• [24]Hattori N, Ikekubo K, Nakaya Y et al.. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metabol. 2005; 90:3036-44.
• [25]Ignacak A et al.. Prolactin–not only lactotrophin. A “new” view of the “old” hormone. J Physiol Pharmacol. 2012; 63(5):435-43.
• [26]Pascoe-Lira D, Duran-Reyes G, Contreras-Hernández I, Manuel-Apolinar L, Blanco-Favela F, Leaños-Miranda A. Frequency of macroprolactinemia due to autoantibodies against prolactin in pregnant women. J Clin Endocrinol Metab. 2001; 86:924-9.
• [27]Jackson RD, Wortsman J, Malarkey WB. Persistence of large molecular weight prolactin secretion during pregnancy in women with macroprolactinemia and its presence in fetal cord blood. J Clin Endocrinol Metab. 1989; 68:1046-50.
• [28]Hattori N. The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. J Clin Endocrinol Metab. 1996; 81:586-90.
• [29]Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012; 2012:167132.
• [30]Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, Ellis PK et al.. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple poly ethylene glycol precipitation method. J Clin Endocrinol Metab. 2001; 86(6):2743-6.
• [31]Ferrari C, Boghen M, Paracchi A et al.. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinol. 1983; 104:35-41.
• [32]Hermite ML, Robyn C, Golstein J et al.. Prolactin and thyrotropin in thyroid diseases: lack of evidence for a physiological role of thyrotropin-releasing hormone in the regulation of prolactin secretion. Horm Metab Res. 1974; 16:190-5.
• [33]Ben-Jonathan N, Mershon JL, Allen DL, Steimetz RM. Extra pituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996; 17:639-69.
• [34]Shahar S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev. 2012; 11(6):A465-70.
• [35]Costanza M, Binart N, Steinman L, Pedotti R. Prolactin: a versatile regulator of inflammation and autoimmune pathology. Autoimmun Rev. 2014; 14(3):223-30.
• [36]Kavanagh-Wright L, Smith TP, Gibney J et al.. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf). 2009; 70:599-605.
• [37]Ishibashi M, Kuzuya N, Sawada S, Kitamura K, Kamoi K, Yamazi T. Anti-thyroid antibodies in patients with hyperprolactinemia. Endocrinol Jpn. 1991; 38:517-22.
• [38]Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev. 2002; 1:360-4.
• [39]Leanos-Miranda A, Pascoe-Lira D, Chavez-Rueda KA et al.. Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity. J Rheumatol. 2001; 28:1546-53.
• [40]Kramer CK, Tourinho TF, de Castro WP, Oliveria MD. Association between systemic lupus erythematosus, rheumatoid arthritis, hyperprolactinemia, and thyroid autoantibodies. Arch Med Res. 2005; 36:54-8.
• [41]Liu H, Shan Z, Li C, Mao J, Xie X, Wang W et al.. Maternal subclinical hypothyroidism. Thyroid autoimmunity and the risk of miscarriage: a prospective cohort study. Thyroid. 2014; 24(11):1642-9.
• [42]Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010; 31(5):702-55.